Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emmaus Needs US FDA Advisory Cmte. To Rescue Sickle Cell Disease Candidate

Executive Summary

FDA reviewers disagree with Emmaus' extrapolation methods for holes in efficacy data for its L-glutamine ahead of May 24 Oncologic Drugs Advisory Committee meeting.

You may also be interested in...



Unmet Need Helped Boehringer's Ofev Win Favorable Advisory Cmte. Vote For New Indication – Or Did It?

US FDA's Arthritis Advisory Committee members who qualified their votes in recommending approval for Ofev to treat SSc-ILD could complicate the agency’s decision.

Unmet Need Can Trump Anything At US FDA Panels, Even An Ill-Prepared Sponsor

Emmaus was unable to answer several questions about its product and was also missing several pieces of data, but FDA's Oncologic Drugs Advisory Committee didn't criticize the sponsor, and instead praised it for paying attention to the largely neglected sickle cell disease.

Sickle Cell Disease Treatment Gets Panel Nod Despite Efficacy Concerns

US FDA's Oncologic Drugs Advisory Committee votes 10-3 in favor of approving Emmaus' L- glutamine, touting its strong safety profile and the unmet clinical need in spite of agency's questions about efficacy results.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel